HROW reports today with a short position that has barely budged since yesterday's preview — and the lending market remains tight enough to make a short squeeze a live risk if the print surprises.
Short interest is 18.3% of the free float, essentially unchanged from the 18.4% flagged in Monday's preview. What has shifted slightly is borrow availability, which has ticked back up to 27.7% from the 25.7% low hit on August 6 — still tight, meaning fewer than one share is available for every three already on loan, but the acute tightening appears to have paused. Borrow costs remain conspicuously cheap at 0.79%, down 18% on the week. That low cost-to-borrow alongside high short interest is the defining tension in the setup: bears are dug in, but they got there cheaply and are not being squeezed out. The ORTEX short score has edged higher to 79.1, ranking HROW in the bottom 4th percentile for short positioning across the coverage universe. The stock added another 0.6% Monday to close at $40.70, extending last week's 4.1% recovery, though it remains roughly 4% lower on the month.
Options traders are not hedging aggressively into the release. The put/call ratio at 0.20 is marginally above its 20-day average of 0.19 and nowhere near its 52-week high of 0.44 — call positioning actually dominates the options market by a wide margin. That stands in contrast to the elevated short interest and makes for a split picture: structural short sellers are firmly positioned, but options traders show no sign of incremental fear.
The bull-bear debate is dominated by one near-term question. Bears point to the Q1 stumble — Vevye sales were hit by high-deductible plan dynamics, and IHEEZO lost pass-through status in the surgical setting in April, triggering distributor destocking and an anticipated price reset. Those headwinds have weighed on results and drove a sharp earnings-day sell-off in May. Bulls counter that the company's long-term ophthalmic portfolio thesis is intact: a $250M quarterly revenue target by 2027, a 26% year-on-year sales growth rate, and clinical data that supports IHEEZO's superior efficacy profile. Analysts covering the name are uniformly positive — BTIG, Cantor Fitzgerald, HC Wainwright, and B. Riley all carry Buy or Overweight ratings, with price targets clustering between $63 and $88 against the current $40.70 price. The EPS surprise factor score, ranking in the 92nd percentile historically, adds one more data point to the bull ledger. The note of caution is that both May prints saw the stock fall more than 20% on the day, suggesting the market remains skeptical of management's ability to execute cleanly.
The earnings release is therefore less a test of Harrow's long-term ophthalmic ambitions and more a test of whether the IHEEZO reset has played out faster than feared — and whether H2 2026 guidance can convincingly bridge the gap between a $40 stock and a Street consensus pointing more than 60% higher.
See the live data behind this article on ORTEX.
Open HROW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
